CA2687931C - Ccr2 receptor antagonists and uses thereof - Google Patents

Ccr2 receptor antagonists and uses thereof Download PDF

Info

Publication number
CA2687931C
CA2687931C CA2687931A CA2687931A CA2687931C CA 2687931 C CA2687931 C CA 2687931C CA 2687931 A CA2687931 A CA 2687931A CA 2687931 A CA2687931 A CA 2687931A CA 2687931 C CA2687931 C CA 2687931C
Authority
CA
Canada
Prior art keywords
amino
phenyl
chloro
methoxy
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2687931A
Other languages
English (en)
French (fr)
Other versions
CA2687931A1 (en
Inventor
Heiner Ebel
Stefan Peters
Silke Hobbie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2687931A1 publication Critical patent/CA2687931A1/en
Application granted granted Critical
Publication of CA2687931C publication Critical patent/CA2687931C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2687931A 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof Active CA2687931C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109376.9 2007-05-31
EP07109376 2007-05-31
PCT/EP2008/056573 WO2008145681A2 (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
CA2687931A1 CA2687931A1 (en) 2008-12-04
CA2687931C true CA2687931C (en) 2016-05-24

Family

ID=38752546

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2687931A Active CA2687931C (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof

Country Status (8)

Country Link
US (1) US8653262B2 (enExample)
EP (1) EP2155689B1 (enExample)
JP (1) JP5603770B2 (enExample)
AR (1) AR066799A1 (enExample)
CA (1) CA2687931C (enExample)
CL (1) CL2008001593A1 (enExample)
TW (1) TW200904434A (enExample)
WO (1) WO2008145681A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
NZ583815A (en) 2007-08-14 2012-03-30 Boehringer Ingelheim Int Aryl Sulfonamides with an Analgesic Action
WO2009076404A1 (en) * 2007-12-10 2009-06-18 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
KR20110053424A (ko) * 2008-08-12 2011-05-23 베링거 인겔하임 인터내셔날 게엠베하 사이클로알킬-치환된 피페라진 화합물의 제조 방법
EP2352501B1 (en) * 2008-11-03 2014-01-01 ChemoCentryx, Inc. Compounds for use in the treatment of osteoporosis
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
MX346393B (es) 2009-12-17 2017-03-17 Centrexion Therapeutics Corp Nuevos antagonistas del receptor ccr2 y usos de los mismo.
EP3050882B1 (en) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
EP2575815A4 (en) 2010-06-04 2013-12-25 Albany Molecular Res Inc GLYCIN TRANSPORTER 1 INHIBITORS, METHODS OF MAKING THE SAME, AND USES THEREOF
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
US9133188B2 (en) * 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
WO2014169087A2 (en) * 2013-04-10 2014-10-16 The Trustees Of Columbia University In The City Of New York Treatment of proximal spinal muscular atrophy
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016128343A1 (en) * 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
CN112457255B (zh) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4329881A4 (en) * 2021-04-30 2025-06-11 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
EP4538264A1 (en) 2022-06-13 2025-04-16 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4426382A (en) 1980-02-13 1984-01-17 Sankyo Company Limited 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
DE3517617A1 (de) 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
ES8802151A1 (es) * 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
CA2146019A1 (en) 1992-10-23 1994-05-11 Howard B. Broughton Dopamine receptor subtype ligands
JP3166376B2 (ja) 1993-02-03 2001-05-14 松下電器産業株式会社 熱利用装置
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JPH1190106A (ja) * 1997-09-26 1999-04-06 Daicel Chem Ind Ltd 擬似移動床式クロマト分離装置
JP4570773B2 (ja) * 1997-10-27 2010-10-27 ニューロサーチ、アクティーゼルスカブ ニコチン性アセチルコリンレセプターに於けるコリン作動性リガンドとしてのヘテロアリールジアザシクロアルカン
CA2350081A1 (en) * 1998-11-20 2000-06-02 G.D. Searle & Co. Process for making 5-substituted pyrazoles using dithietanes
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
EP1046593A1 (en) * 1999-04-12 2000-10-25 Heineken Technical Services B.V. Closure for container
TR200103214T2 (tr) 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
AU5741301A (en) 2000-05-22 2001-12-03 Aventis Pharm Prod Inc Arylmethylamine derivatives for use as tryptase inhibitors
US20050143372A1 (en) 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
CN1628109A (zh) * 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基－与杂芳基－哌嗪
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
MXPA04007775A (es) * 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20040082551A1 (en) 2002-06-05 2004-04-29 Benson Alan G. Novel pyrazoles and their use as p38 kinase inhibitors
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
BRPI0408284B8 (pt) 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
DE602004015269D1 (de) 2003-04-23 2008-09-04 Glaxo Group Ltd Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
ES2291913T3 (es) 2003-07-18 2008-03-01 Glaxo Group Limited Piperidinas sustituidas como ligandos del receptor h3 de la histamina.
AU2004259263B2 (en) * 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
CN102344398B (zh) 2003-12-18 2015-02-25 因赛特公司 作为趋化因子受体调控剂的3-环烷基氨基吡咯烷衍生物
JP4845873B2 (ja) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
JP2007531753A (ja) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
WO2006001958A2 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
MEP8409A (en) 2004-06-02 2011-12-20 Fused heterocyclic compound
CA2570637A1 (en) 2004-06-24 2006-02-02 Wenqing Yao N-substituted piperidines and their use as pharmaceuticals
NZ552173A (en) 2004-06-25 2010-07-30 Janssen Pharmaceutica Nv Quaternary salt CCR2 antagonists
EA012649B1 (ru) 2004-06-28 2009-12-30 Инсайт Корпорейшн 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MX2007002318A (es) 2004-08-26 2007-04-17 Kudos Pharm Ltd Derivados de ftalazinona substituidos con 4-heteroarilmetilo.
GB0420831D0 (en) * 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
UY29219A1 (es) 2004-11-22 2006-04-28 Incyte Corp Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
DE102004061751A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
US7906645B2 (en) * 2004-12-24 2011-03-15 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
EP1853260A1 (en) * 2005-02-16 2007-11-14 Merck & Co., Inc. Substituted pyrazoles as modulators of chemokine receptors
EP2607362B1 (en) 2005-02-17 2014-12-31 Astellas Pharma Inc. Piperidine and piperazine carboxylates as FAAH inhibitors
WO2006113140A2 (en) 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
MX2007015675A (es) * 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
EP1909797A4 (en) * 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
BRPI0616575A2 (pt) 2005-09-27 2011-06-21 Irm Llc compostos e composições contendo diarilamina, seu uso como moduladores de receptores de c-kit bem como método para sua produção
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US20100016289A1 (en) 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
CA2627900A1 (en) 2005-11-14 2007-08-16 Irm Llc Compounds and compositions as lxr modulators
WO2007084868A2 (en) 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2465850B1 (en) 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Therapeutic compounds
EP2024353A2 (en) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
EP2013174B1 (en) 2006-04-11 2013-05-08 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2007127448A2 (en) 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
DK2120579T3 (da) 2006-12-28 2014-02-03 Abbvie Inc Inhibitorer af poly(ADP-ripose)polymerase
AU2008215948A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
JP5303557B2 (ja) 2007-08-22 2013-10-02 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤である２−ヘテロアリールアミノ−ピリミジン誘導体
WO2009043747A2 (en) 2007-10-01 2009-04-09 F. Hoffmann-La Roche Ag N-heterocyclic biaryl carboxamides as ccr receptor antagonists
WO2009067406A1 (en) 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
JP5385297B2 (ja) 2007-11-22 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
JP5432249B2 (ja) 2008-06-18 2014-03-05 エフ．ホフマン−ラ ロシュ アーゲー 新規なヘテロアリールカルボキシアミド誘導体
AU2009279787B2 (en) 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AU2009289378A1 (en) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
AU2010215041A1 (en) * 2009-02-23 2011-07-28 Merck Canada Inc. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
MX346393B (es) 2009-12-17 2017-03-17 Centrexion Therapeutics Corp Nuevos antagonistas del receptor ccr2 y usos de los mismo.
US20130143905A1 (en) 2009-12-17 2013-06-06 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
JP5786257B2 (ja) 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の選択的ｃｃｒ２拮抗薬
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists

Also Published As

Publication number Publication date
JP2010528089A (ja) 2010-08-19
WO2008145681A3 (en) 2009-03-05
WO2008145681A2 (en) 2008-12-04
EP2155689A2 (en) 2010-02-24
TW200904434A (en) 2009-02-01
JP5603770B2 (ja) 2014-10-08
US8653262B2 (en) 2014-02-18
CL2008001593A1 (es) 2009-09-11
US20100204209A1 (en) 2010-08-12
CA2687931A1 (en) 2008-12-04
AR066799A1 (es) 2009-09-16
EP2155689B1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
CA2687931C (en) Ccr2 receptor antagonists and uses thereof
EP2816040B1 (en) Process for the production of CCR2 receptor antagonists and intermediates thereof
EP2721025B1 (en) New selective ccr2 antagonists
US9108958B2 (en) Selective CCR2 antagonists
EP2513086B1 (en) Novel antagonists for ccr2 and uses thereof
EP2569295B1 (en) New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) CCR2 antagonists and uses thereof
US8962656B2 (en) CCR2 antagonists
US9018212B2 (en) Pyridazine carboxamides as CCR2 receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130301

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250519

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250519